Samsung Biologics Receives High Rating for Water Security
Samsung Biologics, a prominent contract development and manufacturing organization (CDMO), has achieved significant recognition for its commitment to water security. Recently, the company received an impressive 'A' rating in Water Security from the Carbon Disclosure Project (CDP), marking a remarkable achievement just two years after joining the CDP assessments.
Exemplary Leadership in Environmental Stewardship
Over the past year, Samsung Biologics has not only maintained its commitment to environmental responsibility but has also attained a rating one step higher than last year's. The CDP 'A List' is a prestigious recognition that highlights businesses demonstrating exceptional leadership in environmental stewardship, with only about 2% of assessed companies making it onto this list. This recognition reflects Samsung Biologics' persistent efforts to adopt and implement exemplary environmental practices.
Samsung's Commitment to Sustainability
Since its establishment in 2000, the CDP has encouraged global enterprises to disclose their environmental impacts and sustainability initiatives. Notably, leading pharmaceutical companies promote participation in CDP assessments among their partners to evaluate progress in climate actions. Achieving top ratings serves as credible external validation of corporate sustainability performance, indicating a company's consistent high ratings in various sectors such as strategy and execution.
In this year's assessment, Samsung Biologics was commended for clearly defining its goals concerning natural capital strategies, water pollution management, and water reuse rates. Furthermore, the company showcased a high level of accuracy and reliability in its reporting on water intake, discharge, and consumption metrics. John Rim, the CEO and President of Samsung Biologics, stated, "This acknowledgment is a reflection of our ongoing efforts to align with the ESG initiatives set forth by our clients around the world. Moving forward, we will persist in striving for carbon neutrality while enhancing our management of water resources."
The Future of Samsung Biologics
In its journey toward sustainability, Samsung Biologics actively contributes as a champion in the Supply Chains Working Group within the Sustainable Markets Initiative (SMI) Health Systems Task Force. This role allows the company to reinforce industry-wide ESG initiatives and demonstrates its dedication as a sustainable CDMO partner. Samsung Biologics aims to transition fully to renewable energy by a set target year, continuing its focus on managing natural capital and minimizing climate impacts throughout its entire value chain—all while working diligently towards carbon neutrality.
About Samsung Biologics
Samsung Biologics stands at the forefront as a leading contract development and manufacturing organization (CDMO). It provides comprehensive services spanning from late-stage discovery to commercial manufacturing. The company operates with a remarkable biomanufacturing capacity of 784,000 liters across five plants, utilizing cutting-edge technologies and expertise to advance various modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics.
The implementation of the ExellenS™ framework within its manufacturing network allows Samsung Biologics to maintain standardized designs and unified processes through advanced digitalization, ensuring plant equivalency and continuity in manufacturing. Samsung Biologics maintains commercial offices across key regions, including Korea, the U.S., and Japan. The firm's operations in America specifically support clients across North America and Europe, while its Tokyo office caters to the APAC region.
To maintain excellence in operational and quality standards, Samsung Biologics continually invests in new capabilities. The company is committed to delivering safe, high-quality products promptly and ensuring that its business decisions contribute positively to society and global health.
Frequently Asked Questions
What rating did Samsung Biologics receive from the CDP?
Samsung Biologics received an 'A' rating in Water Security from the Carbon Disclosure Project (CDP).
How many years has Samsung Biologics participated in CDP assessments?
Samsung Biologics has been participating in CDP assessments for two years.
What does the CDP 'A List' signify?
The CDP 'A List' recognizes companies that exhibit exceptional leadership in environmental stewardship, including only about 2% of assessed businesses.
What are some initiatives Samsung Biologics focuses on for sustainability?
Samsung Biologics focuses on natural capital strategies, water pollution management, and enhancing water reuse rates.
Where is Samsung Biologics headquartered?
Samsung Biologics is headquartered in South Korea and has commercial offices in the U.S. and Japan.
